SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Aptevo Says Mipletamig Combination Enabled 21% of Frontline AML Patients to Reach Transplant

The report describes a clinical outcome for Aptevo’s mipletamig combination in frontline AML patients.

APVO

Related stories